Efficacy of Early Combined Therapy with Metformin and Pioglitazone in Patients with Diabetes Mellitus Type 2
Objective. To assess the efficacy of early treatment with metformin and pioglitazone in type 2 diabetes patients.
Material and methods. Twenty seven patients with decompensated type 2 diabetes mellitus treated with metformin were enrolled into the open-label study. The duration of type 2 diabetes mellitus was 3.6 ± 0.4 years. To achieve glycemic control pioglitazone was added to metformin. Before and after 16-week treatment we evaluated the parameters of carbohydrate and lipid metabolisms, degree of insulin resistance, function of beta-cells, body weight, structural and functional parameters of the heart and heart rhythm.
Results. At 24 weeks, the level of HbA1c decreased by 18.8 % (p < 0.05), fasting glycemia by 34.6 % (p < 0.001), postprandial glycemia by 37.8 % (p < 0.001), HOMA-IR by 57.9 % (p < 0.001). There was no deterioration of beta-cells dysfunction. Combined treatment improved lipid profile and parameters of cardiovascular system.
Conclusion. Early combined treatment with metformin and pioglitazone improved glycemic control and cardiovascular risk factors in type 2 diabetic patients.
Full Text:PDF (Українська)
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020